Indapta Therapeutics is a clinical-stage biotechnology enterprise dedicated to developing and commercializing a proprietary, off-the-shelf, allogeneic natural killer cell therapy designed to treat cancer and autoimmune diseases. The company's therapeutic platform leverages a naturally occurring subset of specialized immune cells known as g-NK cells, which demonstrate enhanced potency against tumor cells and autoreactive lymphocytes without requiring artificial genetic modification. By combining these natural killer cells with approved monoclonal antibodies, Indapta aims to overcome the limitations of conventional cellular therapies for patients.